| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $25,144,033 | 6 | 75 |
Sells | $546,373 | 2 | 25 |
| TANG KEVIN | director | 6 | $25.14M | 0 | $0 | $25.14M |
| Robertson Stephen P. | Chief Legal Officer | 0 | $0 | 2 | $546,373 | $-546,373 |
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and …
Over the last 12 months, insiders at Aurinia Pharmaceuticals Inc. have bought $25.14M and sold $546,373 worth of Aurinia Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Aurinia Pharmaceuticals Inc. have bought $15.71M and sold $7.18M worth of stock each year.
Highest buying activity among insiders over the last 12 months: TANG KEVIN (director) — $25.14M.
The last purchase of 206,005 shares for transaction amount of $3.15M was made by TANG KEVIN (Chief Executive Officer) on 2026‑06‑02.
| 2026-09-10 | Sale | Robertson Stephen P. | Chief Legal Officer | 11,939 0.0092% | $15.95 | $190,427 | +2.76% | |
| 2026-08-21 | Sale | Robertson Stephen P. | Chief Legal Officer | 20,975 0.0164% | $16.97 | $355,946 | -0.96% | |
| 2026-06-02 | TANG KEVIN | Chief Executive Officer | 206,005 0.1599% | $15.28 | $3.15M | +4.87% | ||
| 2026-06-01 | TANG KEVIN | Chief Executive Officer | 343,620 0.2667% | $15.28 | $5.25M | +5.42% | ||
| 2026-05-29 | TANG KEVIN | Chief Executive Officer | 264,981 0.2058% | $15.31 | $4.06M | +5.28% | ||
| 2026-03-03 | TANG KEVIN | director | 184,208 0.1398% | $14.22 | $2.62M | +12.79% | ||
| 2026-03-02 | TANG KEVIN | director | 199,353 0.1522% | $14.26 | $2.84M | +12.32% | ||
| 2026-02-27 | TANG KEVIN | director | 516,439 0.3868% | $13.99 | $7.23M | +12.60% | ||
| 2025-08-05 | TANG KEVIN | director | 200,000 0.1517% | $11.68 | $2.34M | +29.40% | ||
| 2025-08-04 | TANG KEVIN | director | 100,000 0.0821% | $11.34 | $1.13M | +31.35% | ||
| 2025-08-01 | Sale | Keenan Greg | Chief Medical Officer | 20,000 0.0168% | $10.50 | $210,000 | +43.85% | |
| 2025-08-01 | TANG KEVIN | director | 1M 0.8102% | $10.12 | $10.12M | +43.85% | ||
| 2025-03-07 | Sale | Keenan Greg | Chief Medical Officer | 8,305 0.0061% | $8.23 | $68,350 | +44.36% | |
| 2025-03-04 | Sale | Greenleaf Peter | Chief Executive Officer | 164,947 0.1174% | $7.92 | $1.31M | +44.55% | |
| 2025-03-04 | Sale | Donley Matthew Maxwell | Chief Operating Officer | 58,991 0.042% | $7.92 | $467,209 | +44.55% | |
| 2025-03-04 | Sale | Miller Joseph M | Chief Financial Officer | 56,154 0.04% | $7.92 | $444,740 | +44.55% | |
| 2025-03-04 | Sale | Robertson Stephen P. | EVP, General Counsel | 57,607 0.041% | $7.92 | $456,247 | +44.55% | |
| 2025-03-04 | TANG KEVIN | director | 748,038 0.5348% | $7.96 | $5.95M | +44.55% | ||
| 2025-03-03 | Sale | Greenleaf Peter | Chief Executive Officer | 195,593 0.1432% | $8.00 | $1.56M | +45.61% | |
| 2025-03-03 | Sale | Donley Matthew Maxwell | Chief Operating Officer | 65,902 0.0483% | $8.00 | $527,216 | +45.61% |
| TANG KEVIN | Chief Executive Officer | 13044106 9.8038% | $216.01M | 15 | 0 | +25.44% |
| Robertson Stephen P. | Chief Legal Officer | 588848 0.4426% | $9.75M | 1 | 6 | <0.0001% |
| Greenleaf Peter | Chief Executive Officer | 1788945 1.3446% | $29.62M | 1 | 5 | +37.58% |
| Donley Matthew Maxwell | Chief Operating Officer | 680465 0.5114% | $11.27M | 2 | 4 | +67.17% |
| Miller Joseph M | Chief Financial Officer | 577361 0.4339% | $9.56M | 1 | 5 | +37.58% |
| Habig Scott Michael | Chief Commercial Officer | 456338 0.343% | $7.56M | 1 | 3 | +81.51% |
| Martin Michael Robert | Chief Business Officer | 89512 0.0673% | $1.48M | 1 | 15 | +80.79% |
| MILNE GEORGE M JR | director | 70000 0.0526% | $1.16M | 3 | 0 | +0.28% |
| MacKay-Dunn R. Hector | director | 18595 0.014% | $307,933.20 | 3 | 2 | +16.06% |
| Leversage Jill | director | 12918 0.0097% | $213,922.08 | 3 | 2 | <0.0001% |
$21,345,882 | 83 | 94.45% | $2.19B | |
$47,419,530 | 58 | 17.20% | $1.96B | |
$1,376,668 | 53 | 18.46% | $2.1B | |
$108,353,116 | 49 | 15.41% | $2.17B | |
$586,486,795 | 47 | 4.28% | $2.38B |
| Increased Positions | 134 | +50.38% | 12M | +18.2% |
| Decreased Positions | 111 | -41.73% | 5M | -8.1% |
| New Positions | 46 | New | 3M | New |
| Sold Out Positions | 30 | Sold Out | 1M | Sold Out |
| Total Postitions | 289 | +8.65% | 72M | +10.11% |
| Tang Capital Management Llc | $173,908.00 | 8.58% | 11.33M | +1M | +12.96% | 2025-09-30 |
| Blackrock, Inc. | $114,340.00 | 5.64% | 7.45M | -244,298 | -3.18% | 2025-09-30 |
| Nea Management Company, Llc | $60,937.00 | 3.01% | 3.97M | 0 | 0% | 2025-09-30 |
| Arrowstreet Capital, Limited Partnership | $51,791.00 | 2.56% | 3.37M | +2M | +213.54% | 2025-09-30 |
| State Street Corp | $41,349.00 | 2.04% | 2.69M | -101,335 | -3.63% | 2025-09-30 |
| Morgan Stanley | $29,883.00 | 1.48% | 1.95M | -449,454 | -18.76% | 2025-09-30 |
| Vanguard Group Inc | $23,908.00 | 1.18% | 1.56M | -163,369 | -9.49% | 2025-09-30 |
| Geode Capital Management, Llc | $22,805.00 | 1.13% | 1.49M | -91,360 | -5.79% | 2025-09-30 |
| Marshall Wace, Llp | $22,766.00 | 1.12% | 1.48M | +1M | +1,272.51% | 2025-09-30 |
| Renaissance Technologies Llc | $22,251.00 | 1.1% | 1.45M | +291,800 | +25.2% | 2025-09-30 |